- Home
- Equipment
- usa massachusetts
- tumor associated antigens
Refine by
Tumor Associated Antigens Equipment Supplied In Usa Massachusetts
5 equipment items found
Manufactured by:Boston Pharmaceuticals based inCambridge, MASSACHUSETTS (USA)
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
by:Myeloid Therapeutics based inCambridge, MASSACHUSETTS (USA)
Emerging from the Company’s proprietary ATAK™ CAR receptor library, Myeloid’s novel in vivo engineering platform specifically targets and activates myeloid cells to elicit broader anti-tumor adaptive immunity. Through this approach, Myeloid demonstrates that delivery of lipid-nanoparticles (LNPs) encapsulating mRNA results in uptake and selective expression by myeloid cells in ...
Manufactured by:Takeda Pharmaceutical Company Limited based inChuo-ku, JAPAN
Adaptate Biotherapeutics is focussed on therapeutic antibodies which harness the potential of patients’ own gamma delta T cells in situ. Gamma delta T cells play a critical role in immune surveillance, recognising malignant/transformed cells through a pattern of stress markers and exerting potent and selective cytotoxicity. The recognition mechanism is not MHC restricted and not ...
Manufactured by:Mersana Therapeutics based inCambridge, MASSACHUSETTS (USA)
Immunosynthen is our novel immunostimulatory ADC platform designed to take ADCs beyond traditional cytotoxic drugs to targeted stimulation of the innate immune system. Through the safe and efficient delivery of a novel immunomodulatory STING agonist, ADCs created with our Immunosynthen platform have the potential to address the challenges of efficacy, delivery and tolerability. Stimulator of ...
by:Sumitomo Pharma Oncology, Inc. based inCambridge, MASSACHUSETTS (USA)
Immunotherapeutic cancer vaccines have generated a lot of interest from oncologists since it was discovered that immune activation can lead to a specific antitumor response.1 However, despite initial progress, most cancer vaccines have failed to drive sufficient tumor immunogenicity, leading to poor clinical responses.1 The reason for this may be that previous vaccine models used inadequate ...